| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03287050 Details | 2021-12-15 Interventional | 2 | 6 | Pembrolizumab Carcinoma Carcinoma, Tran… Urothelial Carc… | due to changing therapeutic landscape in metastatic bladder cancer and lack of
radiation/immunotherapy systemic synergy in other malignancies This study was closed early (at 6 patients) due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies. | |||
| NCT03181828 NCT02670889 Details | 2021-12-15 Interventional | 1/2 | 4 | Acetohydroxamic… Urea Cycle Diso… Urea Cycle Diso… | The incidence of AEs was higher than the IB reported. - | |||
| NCT04118036 Details | 2021-12-14 Interventional | 2 | 0 | Pembrolizumab Glioblastoma | Safety concerns - | |||
| NCT03059511 Details | 2021-12-14 Interventional | 1 | 51 | Nalbuphine Pharmacokinetic | We conclude that the doses we administered were safe, but too low. We plan to continue the
study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal). - | |||
| NCT03990077 Details | 2021-12-10 Interventional | 1 | 2 | Docetaxel Carcinoma, Non-… Nsclc | drug development strategy adjustment - | |||
| NCT04750759 Details | 2021-12-09 Interventional | 2 | 4 | Camostat Niclosamide COVID-19 Covid19 | sub-therapeutic plasma levels of active substance - | |||
| NCT04526821 Details | 2021-12-09 Interventional | 2 | 209 | Lactoferrin SARS-CoV-2 | The study was interrupted due to the arrival and distribution of the vaccine to hospital
workers in Peru - | |||
| NCT02832687 Details | 2021-12-09 Interventional | 4 | 88 | Acetaminophen Recovery Follow… | The study was halted due to the worldwide COVID-19 pandemic and the cancellation of all
elective cases. - | |||
| NCT02587598 Details | 2021-12-08 Interventional | 1/2 | 97 | Azacitidine Cytarabine Neoplasms Solid Tumors | - - | |||
| NCT01018563 2009-015825-36 Details | 2021-12-08 Interventional | 2 | 3 | Farletuzumab Carcinoma, Ovar… Ovarian Neoplas… Epithelial Ovar… | Study was terminated by sponsor due to futile results in NCT00849667 study. Study was terminated by sponsor due to futile results in the NCT00849667 (MORAb003-004) study. | |||
| NCT05116800 Details | 2021-12-07 Interventional | 2 | 0 | Docetaxel Gemcitabine Hemangiosarcoma Histiocytoma, M… Leiomyosarcoma Liposarcoma Osteosarcoma Rhabdomyosarcom… Sarcoma Sarcoma, Ewing Sarcoma, Synovi… Angiosarcoma Bone Sarcoma Ewing Sarcoma o… High Grade Sarc… Myxofibrosarcom… Soft Tissue Sar… Spindle Cell Sa… Synovial Sarcom… Undifferentiate… | IND withdrawn - | |||
| NCT03797261 2018-003314-41 Details | 2021-12-07 Interventional | 1 | 9 | Venetoclax Hematologic Neo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Non-H… Acute Myeloid L… Diffuse Large B… Non-Hodgkin's L… | Safety - | |||
| NCT03344341 Details | 2021-12-07 Interventional | 4 | 304 | Acarbose Dapagliflozin Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | Study overall progress behind of scheduled timeline. Study was terminated early due to company
decision. - | |||
| NCT03212963 Details | 2021-12-07 Interventional | 4 | 16 | Clobetasol Halobetasol Psoriasis Plaque Psoriasi… | Sponsor's Decision - | |||
| NCT03135262 2016-002480-34 Details | 2021-12-07 Interventional | 1/2 | 29 | Obinutuzumab Rituximab Venetoclax Lymphoma Lymphoma, Folli… Lymphoma, Large… Follicular Lymp… | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. Dose expansion part of the study did not take place. AEs were not differentiated for DLBCL and FL arms since these are sub mutations of disease which does nor show differences in AEs. | |||
| NCT00472186 Details | 2021-12-06 Interventional | 4 | 2 | Dexlansoprazole Lansoprazole Post-tonsillect… Post-tonsillect… Post-tonsillect… | Poor compliance with returning of logbooks by families. Two patients were enrolled. Only one
returned the logbook and therefore not analyzed - | |||
| NCT04371640 Details | 2021-12-03 Interventional | 1 | 0 | Sirolimus COVID-19 Covid-19 SARS-CoV-2 | Study population not regularly admitted to hospital and approaches have shifted away from
repurposing old drugs. - | |||
| NCT03644550 Details | 2021-12-02 Interventional | 2 | 18 | LMB-100 Pembrolizumab Mesothelioma Mesothelioma, M… | Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first
line treatment for Mesothelioma, the principal investigator decided to end the study early
(prior to reaching enrollment goal). - | |||
| NCT02564796 Details | 2021-12-02 Interventional | 2 | 4 | Epoetin Alfa Iron Cyanosis Heart Defects, … Heart Diseases Anemia Congenital Hear… Cyanotic Congen… | COVID The principal investigator discussed the study's future with the sub-investigators on the study and came to the conclusion to terminate the study early due to low enrollment while also considering the financial costs to continue to run the study. It would be highly improbable to be able to enroll 54 more patients with the amount of funding left in the grant. No subjects were analyzed. | |||
| NCT03993379 Details | 2021-12-01 Interventional | 2 | 3 | Ipilimumab Melanoma Neoplasms Solid Tumor Unresectable or… | Sponsor's Decision Due to developmental strategic reasons and slow enrollment because of the COVID-19 pandemic, the study was terminated early. Three subjects were enrolled, all in Cohort A2. The last subject observation for this study was on 21 May 2020. Since the study terminated early, a statistical analysis plan was not generated. |